950772-65-3

Upstream product

• 950771-83-2 8-(propyloxy)-1,4-dioxaspiro[4.5]decane 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 22428-87-1 4,4-ethylenedioxycyclohexan-1-ol 
• 75-16-1 methylmagnesium bromide 
• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 
• 158836-67-0 4-(propyloxy)cyclohexanone 

Downstream Products

• 950772-67-5 cis N-(5-methyl-2-nitrophenyl)-1-[1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinamine 
• 950772-68-6 trans N-(5-methyl-2-nitrophenyl)-1-[1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinamine 
• 950772-69-7 (2-amino-5-methylphenyl){1-[cis-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinyl}amine 
• 950772-70-0 (2-amino-5-methylphenyl){1-[trans-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinyl}amine 

Relevant academic research and scientific papers

1- (1-CYCLOHEXYL-4-PIPERIDINYL) -1, 3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE

Compounds of formula (I) or a salt thereof are provided, wherein X1, X2, X3, R6, Q and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating

BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE

Compounds of formula (I), salts and solvates are provided: formula (I), wherein Q, R and R6 are as defined in the claims. Uses of the compounds for therapy, for example in the treatment of psychotic disorders and cognitive impairment, are also disclosed.